{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "AUD", "exchange": "ASX", "shortName": "CLINUVEL FPO", "longName": "Clinuvel Pharmaceuticals Limited", "messageBoardId": "finmb_6117181", "exchangeTimezoneName": "Australia/Sydney", "exchangeTimezoneShortName": "AEST", "gmtOffSetMilliseconds": 36000000, "market": "au_market", "esgPopulated": false, "marketState": "POSTPOST", "regularMarketChangePercent": 0.85728735, "regularMarketPrice": 20.0, "trailingPE": 50.0, "trailingAnnualDividendYield": 0.0020171457, "epsTrailingTwelveMonths": 0.4, "epsForward": 0.65, "epsCurrentYear": 0.58, "priceEpsCurrentYear": 34.48276, "sharesOutstanding": 49410300, "bookValue": 2.817, "fiftyDayAverage": 19.6706, "fiftyDayAverageChange": 0.3293991, "fiftyDayAverageChangePercent": 0.016745757, "twoHundredDayAverage": 20.621, "twoHundredDayAverageChange": -0.6210003, "twoHundredDayAverageChangePercent": -0.030114945, "marketCap": 988206016, "forwardPE": 30.769232, "priceToBook": 7.099752, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 981932400000, "priceHint": 2, "regularMarketChange": 0.17000008, "regularMarketTime": 1683871827, "regularMarketDayHigh": 20.17, "regularMarketDayRange": "19.69 - 20.17", "regularMarketDayLow": 19.69, "regularMarketVolume": 48305, "regularMarketPreviousClose": 19.83, "bid": 19.94, "ask": 20.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "ASX", "financialCurrency": "AUD", "regularMarketOpen": 20.0, "averageDailyVolume3Month": 83980, "averageDailyVolume10Day": 72871, "fiftyTwoWeekLowChange": 6.84, "fiftyTwoWeekLowChangePercent": 0.51975685, "fiftyTwoWeekRange": "13.16 - 28.72", "fiftyTwoWeekHighChange": -8.719999, "fiftyTwoWeekHighChangePercent": -0.30362114, "fiftyTwoWeekLow": 13.16, "fiftyTwoWeekHigh": 28.72, "earningsTimestamp": 1677194056, "earningsTimestampStart": 1677194056, "earningsTimestampEnd": 1677194056, "trailingAnnualDividendRate": 0.04, "symbol": "CUV.AX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "535 Bourke Street", "address2": "Level 11", "city": "Melbourne", "state": "VIC", "zip": "3000", "country": "Australia", "phone": "61 3 9660 4900", "fax": "61 3 9660 4909", "website": "https://www.clinuvel.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PR\u00c9NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA", "age": 59, "title": "CEO, MD & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 3664177, "fmt": "3.66M", "longFmt": "3,664,177"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Darren M. Keamy", "age": 49, "title": "CFO & Company Sec.", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 413748, "fmt": "413.75k", "longFmt": "413,748"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dennis J. Wright", "title": "Chief Scientific Officer", "fiscalYear": 2022, "totalPay": {"raw": 326652, "fmt": "326.65k", "longFmt": "326,652"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Lachlan  Hay", "title": "Director of Global Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Malcolm  Bull", "title": "Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}